Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
p53 antibody response in patients with vulvar cancer
Autore:
Mayerhofer, K; Hefler, L; Schindl, M; Concin, N; Frischmuth, K; Leodolter, S; Zeillinger, R; Reinthaller, A; Kainz, C;
Indirizzi:
Univ Vienna, Dept Obstet & Gynecol, Sch Med, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 necol, Sch Med, A-1090 Vienna, Austria
Titolo Testata:
ANTICANCER RESEARCH
fascicolo: 3B, volume: 19, anno: 1999,
pagine: 2323 - 2326
SICI:
0250-7005(199905/06)19:3B<2323:PARIPW>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
TUMOR-SUPPRESSOR GENE; SQUAMOUS-CELL CARCINOMA; BREAST-CANCER; PROTEIN OVEREXPRESSION; SERUM ANTIBODIES; IMMUNE-RESPONSE; OVARIAN-CANCER; AUTOANTIBODIES; EPITOPES; DISEASE;
Keywords:
p53 gene; serum; p53 antibodies; vulvar cancer; prognosis;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
32
Recensione:
Indirizzi per estratti:
Indirizzo: Mayerhofer, K Univ Vienna, Dept Obstet & Gynecol, Sch Med, Wahringer Guertel 18-20, A-1090 Vienna, Austria Univ Vienna Wahringer Guertel 18-20 Vienna Austria A-1090 a
Citazione:
K. Mayerhofer et al., "p53 antibody response in patients with vulvar cancer", ANTICANC R, 19(3B), 1999, pp. 2323-2326

Abstract

Background: Mutations in the p53 tumor supressor gene are the most common genetic changes identified in cancer cells. Several studies report alterations of the p53 gene in vulvar cancer. As observed in a wine variety of human malignomas, mutant p53 protein may provoke a specific humoral immune response. The possible occurrence of p53 antibodies in patiens with vulvar cancer has not been investigated so far. Materials and Methods: We used a specific p53 antibody ELISA to investigate serum samples of 41 patients with vulvar cancer taken prior to therapy and serum samples of 17 healthy controls. Results: Of the 41 patients with vulvar cancer, 4 (10%) were found to be positive for serum p53 antibodies, contrary to the 17 healthy volunteers without p53 serum antibodies (chi-square test, p=0.2). No significant correlations were found between p53 antibody status and tumor stage (p=0.64) histological grade (p=0.89), and patients' age (p=0.87). We found no significant association between the p53 serum antibody status in vulvar cancer patientsand disease-free (p=0.67) and overall survival (p=0.7). Conclusions: In summary, if is the first time that p53 antibodies have been defected in the sera of patients with vulvar cancer. However, p53 serum antibodies did not serve as prognostic markers in vulval cancer.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/08/20 alle ore 05:57:12